Strategic funding EpiEndo is a clinical-stage biopharma with recent convertible bond financing totaling around €9 million, signaling ongoing investor interest and potential for partnering discussions, licensing deals, or milestone-based collaborations to accelerate development.

Lead asset focus The company concentrates on glasmacinal (EP395), an orally available macrolide with reduced antimicrobial resistance potential, targeting chronic respiratory diseases—a clear opportunity to approach specialty pharma and CROs for late-stage planning, trials, or co-development partnerships.

Academic collaboration Recent partnership with Lund University and presentations on EP395 data indicate openness to academia-driven research alliances, enabling BD approaches for joint research programs, access to preclinical data, and expanded validation opportunities.

Regulatory and market positioning As a small Icelandic firm with a global clinical focus, there is potential to leverage regional regulatory expertise and strategic alliances to streamline global trial execution, manufacturing partnerships, and market access planning for respiratory inflammatory therapies.

Clinical and commercial signals Active communication around chronic inflammatory indications and a track record of science advisory board involvement suggest opportunities to engage with specialty suppliers, contract research organizations, and healthcare providers for early clinical development collaborations and advisory services.